Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Jaspal Kaeda, Frauke Ringel, Christian Oberender, Ken Mills, Concetta Quintarelli, Fabrizio Pane, Steffen Koschmieder, Robert Slany, Rolf Schwarzer, Giuseppe Saglio, Philipp Hemmati, Antje Van Lessen, Leila Amini, Martin Gresse, Elisabetta Vagge, Thomas Burmeister, Anna Serra, Anne Carson, Michaela Schwarz, Jörg WestermannFranziska Jundt, Bernd Dörken, Philipp Le Coutre

Research output: Contribution to journalArticlepeer-review


A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p <0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p <0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABL1 mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.

Original languageEnglish
Pages (from-to)2105-2113
Number of pages9
JournalLeukemia and Lymphoma
Issue number7
Publication statusPublished - Jul 1 2015


  • Leukemia
  • MSI2
  • Prognosis
  • Stem cell
  • Transformation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this